Breaking News

Ocera Appoints Chief Development Officer

August 12, 2014

Patni brings leadership experience from Roche, Novartis and Pfizer

Rajiv Patni, M.D. has been appointed chief development officer at Ocera Therapeutics, Inc., effective September 2, 2014. Dr. Patni previously served as senior vice president for Actelion U.S. He also served as vice president at Roche and held leadership positions at Novartis and Pfizer.
 
"I am delighted to have Rajiv join our management team and expect that he will make significant contributions to the development of OCR-002," said Linda Grais, M.D., chief executive officer of Ocera. "Rajiv has been involved in over 15 clinical development programs, across several therapeutic areas, including acute care indications. Rajiv also served as an academic physician and trained in internal medicine and cardiology. Rajiv's experience both in the clinic and in industry will be an invaluable asset to Ocera."
 
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision